Kidney Injury and Androgen Deprivation Therapy

Androgen deprivation therapy (ADT) for nonmetastatic prostate cancer, though somewhat common, remains controversial, given both the lack of level-1 evidence to support its routine use and the associated risks for adverse effects, including metabolic syndrome, osteoporosis, and impact on libido. Considering that ADT may also have a negative impact on renal function, as a result of treatment-induced testosterone suppression and its downstream consequences, investigators sought to determine the potential impact of ADT on the risk for acute kidney injury (AKI).

The researchers conducted a retrospective, nested, case-control analysis involving 10,250 men (age, ≥40) with nonmetastatic prostate cancer diagnosed from 1998 through 2008, with follow-u…